AVASTIN Drug Profile
✉ Email this page to a colleague
Summary for Tradename: AVASTIN
| High Confidence Patents: | 24 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for AVASTIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AVASTIN |
Recent Clinical Trials for AVASTIN
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Miami | Phase 1/Phase 2 |
| ImmunityBio, Inc. | Phase 2 |
| Harbin Medical University | Phase 2 |
Recent Litigation for AVASTIN
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| GENENTECH, INC. v. DR. REDDYS LABORATORIES, INC. | 2023-11-17 |
| Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd. | 2023-10-20 |
| Genentech, Inc. v. Biogen MA Inc. | 2023-07-13 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Illumina, Inc. et al. | 2021-07-20 |
| Laboratory Corporation of America Holdings et al. | 2021-05-28 |
| Quest Diagnostics Incorporated | 2021-04-15 |
Pharmacology for AVASTIN
| Mechanism of Action | Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions |
| Established Pharmacologic Class | Vascular Endothelial Growth Factor Inhibitor |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for AVASTIN Derived from Brand-Side Litigation
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2031-08-18 |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2024-05-28 |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2035-07-14 |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2029-03-11 |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Sign Up | 2034-03-14 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
2) High Certainty: US Patents for AVASTIN Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2014-01-25 | Company disclosures |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2020-08-05 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for AVASTIN Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2035-03-27 | Patent claims search |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2032-09-12 | Patent claims search |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2035-12-11 | Patent claims search |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2034-02-06 | Patent claims search |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | ⤷ Sign Up | 2035-03-30 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for AVASTIN
Supplementary Protection Certificates for AVASTIN
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| CA 2006 00025 | Denmark | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB |
| 300238 | Netherlands | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060630 |
| 2006C/035 | Belgium | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/06/346/001 20060628 |
| 06C0024 | France | ⤷ Sign Up | PRODUCT NAME: NATALIZUMAB,ANTICORPS MONOCLONAL HUMANISE ANTI-INTEGRINE ALPHA-4; REGISTRATION NO/DATE: EU/1/06/346/001 20060627 |
| SPC 025/2006 | Ireland | ⤷ Sign Up | SPC 025/2006: 20070523, EXPIRES: 20200124 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
